Inhaled mRNA therapy takes on solid tumors in first human trial
NCT ID NCT07657611
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests an inhaled mRNA immunotherapy for adults with advanced lung cancer or solid tumors that have spread to the lungs. The treatment is given as a dry powder through an inhaler. The main goal is to check safety and find the best dose, with 60 participants expected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Inhaled mRNA dry powder formulation
What this could lead to
If it works, this could point toward a new way to treat advanced solid tumors using inhaled mRNA immunotherapy, potentially offering a non-invasive option.
What could go wrong
This is an early-phase trial with only 60 participants, focused on safety and dosing. It is too soon to know if it will be effective, and there may be unknown side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.